Zonisamide for Heavy Drinkers With Bipolar Disorder (ZNSBP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01566370|
Recruitment Status : Terminated (recruitment infeasible)
First Posted : March 29, 2012
Results First Posted : April 22, 2016
Last Update Posted : January 13, 2017
This is a randomized, double blind, placebo controlled trial of the medication zonisamide for the purpose of reducing heavy drinking and drinking, as well as reducing mood symptoms, in bipolar subjects that drink excessively and heavily.
Hypotheses: (Primary aims); Add-on zonisamide compared to placebo will result in:
- significant reduction in heavy drinking days, drinks per week and per drinking day, and significantly greater increase in abstinent days, ii) greater rates of abstinence and abstinence to heavy drinking, greater reduction in biomarkers of heavy alcohol use such as gamma-glutamyl transferase (GGT), and greater reduction in alcohol urge or "craving",
- Significant reduction in prevalent mood symptoms on the BRMS and BRMeS, CARS, HAMD, or no worsening of euthymic mood, and significant improvement on the Clinical Global Impressions Scale-Severity.
- (Secondary aims) Add-on zonisamide compared to placebo will result in significant reduction in weight (kilograms) and other secondary weight-related metabolic factors such as fasting glucose, lipid profile, and blood pressure.
- (Secondary aims) Add-on zonisamide compared to placebo will result in improved clinical global impression, overall functioning, quality of life, and reduced medical symptoms.
5.) (Exploratory Aims) To will examine interactions between genotype and medication on treatment response for allelic variation in genetic loci related to the major neurotransmitter and neurophysiologic pathways that are relevant to bipolar disorder, alcoholism, and zonisamide mechanism of action.
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Use Disorders Bipolar Disorder||Drug: Zonisamide Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Zonisamide for Heavy Drinkers With Bipolar Disorder|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||July 2013|
Subjects will receive zonisamide titrated to a target dose of 500mg orally, daily, double-blind
titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
Other Name: Zonegran
Placebo Comparator: Placebo
Patients will receive placebo pills that are made to match the zonisamide medication (via over-encapsulation, double-blind, subjects will receive same number of capsules as the active medication group
- Percentage of Total Heavy Drinking Days [ Time Frame: from week 11 through 14 (over 4 weeks) ]The percentage of total heavy drinking days compared between groups (zonisamide and placebo) during the time spent on the target dose of the medication (i.e., not including the titration or taper periods), totaled between the time-points of weeks 11 and 14 (4 weeks time frame).
- Change on Hamilton Depression Rating Scale [ Time Frame: 14 weeks ]Change from baseline to endpoint in Hamilton scores compared between medication and placebo, using repeated measures
- Change in Clinician Assisted Rating Scale for Mania (CARS-M) Scores [ Time Frame: 14 weeks ]Comparison between groups on change in scores on the CARS-M over 14 weeks from baseline to endpoint, measured weekly and analyzed with repeated measures
- Percentage of Abstinent Days [ Time Frame: over four weeks, from week 11 through 14 ]The difference in total percentage of abstinent compared between groups (zonisamide and placebo) during the time spent on the target dose of the medication (i.e., not including the titration or taper periods), which includes week 11, 12, 13, and 14.
- Change in Alcohol Urge Questionnaire Score [ Time Frame: from baseline to endpoint, 14 weeks ]This is the change in AUQ scores (urge to drink) measured weekly compared between groups using repeated measures
- Change in Gamma Glutamyl Transferase (GGT) [ Time Frame: 14 weeks ]Difference between groups on change in levels of GGT over time, measured at baseline, week 5, week 9, week 13, and endpoint, using repeated measures
- Change in Beck Depression Inventory (BDI) Scores [ Time Frame: 14 weeks ]Comparison between groups on change in BDI scores over the 14 weeks of the study, measured weekly, using repeated measures
- Percentage of Total Drinking Days [ Time Frame: 4 weeks ]The percentage of total drinking days compared between groups (zonisamide and placebo) during the time spent on the target dose of the medication (i.e., not including the titration or taper periods), which includes week 11, 12, 13, and 14.
- Change in Number of Heavy Drinking Days Per Week by Time [ Time Frame: 14 weeks (baseline to endpoint) ]A comparison between medication and placebo on the measure of number heavy drinking days per week over the course of the study (baseline to endpoint) via interaction with time using repeated measures
- Change in Number of Drinks Per Week by Time [ Time Frame: 14 weeks (baseline to endpoint) ]Comparison between medication and placebo groups on the change in number of drinks per week via interaction with time (from baseline to endpoint) using repeated measures
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01566370
|United States, Connecticut|
|VA Connecticut Healthcare System|
|West Haven, Connecticut, United States, 06516|
|Principal Investigator:||Albert J Arias, MD||Yale University, VA CT Health System|